Soligenix Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Soligenix Contact Number

Contact Soligenix

Just Now Soligenix.com Show details

609-538-8200To contact Soligenix, fill out the contact form, call at 609-538-8200, fax at 609-452-6467, or via one of these other forms of communication.

Category: Contact SupportShow more

Soligenix Crunchbase Company Profile & Funding

9 hours ago Crunchbase.com Show details

609-538-8200Contact Email [email protected]soligenix.com. Phone Number +1 609-538-8200. Soligenix is a late-stage research and development biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatment and serious gastrointestinal diseases where there remains an unmet medical need, as well as developing

Founded: 1987

Category: Contact NumberShow more

LateStage Biopharmaceutical Company Soligenix

6 hours ago Soligenix.com Show details

Soligenix Granted Pediatric Investigational Plan Waiver for HyBryte™ in CTCL in the United Kingdom. Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet…. Read More. External Link.

Category: Contact NumberShow more

Christopher Schaber's email & phone Soligenix, Inc.'s

6 hours ago Rocketreach.co Show details

Christopher Schaber's email address c*****@soligenix.com 609538. Show email & phone number >>> Rocketreach finds email, phone & social media for 450M+ professionals. Try for free at rocketreach.co

Category: Phone NumberShow more

Soligenix Company Profile Office Locations, Competitors

6 hours ago Craft.co Show details

Soligenix has 14 employees at their 1 location and $2.36 M in annual revenue in FY 2020. See insights on Soligenix including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.

Employees: 14
Type: Public
Founded: 1987
Location: 29 Emmons Dr, Princeton, US

Category: Contact NumberShow more

Soligenix, Inc. in Dover, DE Company Information & Reviews

7 hours ago Bizapedia.com Show details

Soligenix, Inc. is a Delaware Corporation filed On January 16, 1987. The company's File Number is listed as 2115033. The Registered Agent on file for this company is National Registered Agents, Inc. and is located at 160 Greentree Dr Ste 101, Dover, DE 19904.

Location: DE

Category: Contact NumberShow more

SOLIGENIX UK LIMITED overview Find and update company

5 hours ago Find-and-update.company-information.service.gov.uk Show details

SOLIGENIX UK LIMITED. Company number 06560847. Follow (06560847) People for SOLIGENIX UK LIMITED (06560847) More for SOLIGENIX UK LIMITED (06560847) Registered office address Vision Park Chivers Way, Histon, Cambridge, England, CB24 9AD . Company status Contact us Accessibility statement

Category: Contact NumberShow more

Company Information For Soligenix Uk Limited. Registered

8 hours ago Onlinefilings.co.uk Show details

Free Business Information for Soligenix Uk Limited. A Private Limited Company Registered With Companies House Number 06560847 and a Registered Office Located at: Vision Park Chivers Way Histon Cambridge CB24 9AD. Get the Financial Accounts, Activities, Directors List and Shareholders Contact Details.

Category: Contact NumberShow more

Soligenix, Inc. Email Format soligenix.com Emails

6 hours ago Rocketreach.co Show details

Soligenix, Inc. uses 6 email formats: 1. first_initial [email protected]soligenix.com (63.3%). Enter a name to find & verify an email >>> we have a process in place the begins with RocketReach and ends with huge contact lists for our sales team..it probably saves Feedtrail about 3 months of work in terms of lead gathering. With the shear number of

Category: Contact NumberShow more

SOLIGENIX, INC. (Form: 8K, Received: 04/13/2021 07:06:00)

2 hours ago Content.edgar-online.com Show details

900-21-0212CiVax™ development is being funded through an SBIR grant from NIAID (grant number 1 R44 AI157593-01). About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Category: Contact NumberShow more

Oreola Donini Donini Soligenix, Inc NJ USA Database

6 hours ago Bestdataprovider.com Show details

Oreola Donini Donini is serving as SVP/Chief Scientific Officer in the Soligenix, Inc is an active company headquartered in Princeton, NJ in the states of NJ.The Soligenix, Inc office address is located at 29 Emmons Drive, Princeton, NJ, 08540, United States.The company comes under Biotech/Healthcare->BioTech/Drugs industries.

Category: Contact NumberShow more

SOLIGENIX, INC. : Shareholders Board Members Managers and

4 hours ago Marketscreener.com Show details

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing the products to treat rare diseases. The Company operates through two segments: Specialized BioTherapeutics and Public Health Solutions.

Category: Contact NumberShow more

Soligenix, Inc. (SNGX) Company Profile & Overview Stock

6 hours ago Stockanalysis.com Show details

Company profile for Soligenix, Inc. (SNGX) with a description, list of executives, contact details and other key facts. Company profile for Soligenix, Inc. (SNGX) with a description, list of executives, contact details and other key facts. CUSIP Number: 258094101: ISIN Number: US8342233074: Employer ID: 41-1505029: Key Executives. Name

Category: Contact NumberShow more

Soligenix Announces Publication Demonstrating Enduring

7 hours ago Ir.soligenix.com Show details

021-11-04PRINCETON, N.J., Nov. 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today publication of pre-clinical immunogenicity studies for RiVax ® (heat …

Category: Contact NumberShow more

Soligenix Granted Pediatric Investigational Plan Waiver

Just Now Biospace.com Show details

PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a Pediatric Investigation Plan (PIP) product-specific …

Category: Contact NumberShow more

Soligenix Granted Pediatric Investigational Plan Waiver

6 hours ago Ih.advfn.com Show details

PRINCETON, N.J., Nov. 8, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been granted a Pediatric Investigation Plan (PIP) product …

Category: Contact NumberShow more

Soligenix Announces Recent Accomplishments And Third

9 hours ago Prnewswire.com Show details

Financial Results – Quarter Ended September 30, 2021. Soligenix's revenues for the quarter ended September 30, 2021 were $0.2 million as compared to $0.6 million for the quarter ended September

Category: Contact NumberShow more

Soligenix Announces Recent Accomplishments And Third

2 hours ago Markets.businessinsider.com Show details

Soligenix's revenues for the quarter ended September 30, 2021 were $0.2 million as compared to $0.6 million for the quarter ended September 30, 2020.Revenues primarily included payments on grants

Category: Contact NumberShow more

Soligenix Announces Recent Accomplishments And Third

6 hours ago Ih.advfn.com Show details

PRINCETON, N.J., Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the quarter ended …

Category: Contact NumberShow more

Soligenix Announces Positive Preclinical Data with

2 hours ago Bloomberg.com Show details

021-08-18Soligenix Announces Positive Preclinical Data with Multiple Heat Stable Filovirus Vaccine Candidates - Potent efficacy data using purified antigens and CoVaccine HT™ adjuvant demonstrated in non

Category: Contact NumberShow more

def14a0810_soligenix.htm SEC

Just Now Sec.gov Show details

The Annual Meeting of Stockholders of Soligenix, Inc., will be held at the Hyatt Place Princeton, 3565 US Highway 1, Princeton, New Jersey 08540, on September 23, 2010, at 10:00 a.m., Eastern Daylight Time, for the following purposes, each as more fully described herein: The number of shares beneficially owned by Mr. Myrianthopoulos does

Category: Contact NumberShow more

Soligenix Number of Employees 20062021 SNGX MacroTrends

6 hours ago Macrotrends.net Show details

Number of Employees. Soligenix number of employees from 2006 to 2021. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per …

Category: Contact NumberShow more

Soligenix and Intrexon Pursue Melioidosis Therapy Through

9 hours ago Fiercebiotech.com Show details

(609) 538-8200For more information regarding Soligenix, Inc., contact: Joe Warusz, CPA Acting Chief Financial Officer (609) 538-8200 www.soligenix.com For more information regarding Intrexon Corporation, contact:

Category: Contact NumberShow more

Soligenix Announces Recent Accomplishments And Second

5 hours ago Finance.yahoo.com Show details

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet

Category: Contact NumberShow more

SOLIGENIX, INC. (Form: 8K, Received: 03/19/2020 06:06:55)

2 hours ago Content.edgar-online.com Show details

900-20-0068The Phase 3 CTCL clinical study was partially funded by the National Cancer Institute via a Phase II SBIR grant (#1R44CA210848-01A1) awarded to Soligenix, Inc. About Soligenix, Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

Category: Contact NumberShow more

Phase 3 Study of SGX301 and Fluorescent Light for

3 hours ago Sbir.gov Show details

tumor stageCTCL is an orphan disease with no approved first line therapyThe active pharmaceutical. ingredient of Soligenix s SGXtechnology is synthetic hypericina photo activated agent that intracellularly. concentrates in the endoplasmic reticulum andwith activation by visible lightgenerates singlet oxygen that causes.

Category: Contact NumberShow more

Thermostable Vaccine Technology Platform to be Presented

5 hours ago Prnewswire.com Show details

PRINCETON, N.J., Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products

Category: Tech SupportShow more

Soligenix, Inc. (SNGX) Fields Kupka & Shukurov LLP

3 hours ago Fksfirm.com Show details

INVESTIGATION ALERT: Fields Kupka & Shukurov LLP is investigating breach of fiduciary duty claims involving the board of directors of Soligenix, Inc. (NASDAQ:SNGX). If you are a shareholder of Soligenix, Inc. and wish to receive additional information about the investigation and your rights, please fill out and submit the following form. Please note that the submission …

Category: Contact NumberShow more

SOLIGENIX, INC. : SNGX Stock Price US8342233074

6 hours ago Marketscreener.com Show details

Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing the products to treat rare diseases. The Company operates through two segments: Specialized BioTherapeutics and Public Health Solutions. Specialized BioTherapeutics segments includes developing of SGX301 (synthetic hypericin) a photodynamic therapy

Category: Contact NumberShow more

Soligenix Announces Recent Accomplishments And Third

6 hours ago Marketwatch.com Show details

021-11-12Soligenix's revenues for the quarter ended September 30, 2021 were $0.2 million as compared to $0.6 million for the quarter ended September 30, 2020. Revenues primarily included payments on grants

Category: Contact NumberShow more

SNGX: Durable Immunity for RiVax® Vaccine…

3 hours ago News.yahoo.com Show details

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update RiVax® Demonstrates Durable Immunity in Mouse Model On November 4, 2021, Soligenix, Inc. (NASDAQ:SNGX) announced the publication of preclinical studies for RiVax®, the company’s heat stable ricin toxin vaccine) that showed durable …

Category: Contact NumberShow more

Soligenix Announces Recent Accomplishments And Third

8 hours ago Benzinga.com Show details

PRINCETON, N.J., Nov. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products

Category: Contact NumberShow more

Soligenix Stock Today SNGX 0.91 0.01 (1.087%)

6 hours ago Macroaxis.com Show details

Soligenix is trading at 0.91 as of the 14th of November 2021; that is -1.09 percent down since the beginning of the trading day. The stock's open price was 0.92. Get the latest Soligenix detailed stock quotes, stock trade data, stock price info, and performance analysis, including Soligenix Stock investment advice, charts, stats and more.

Category: Contact NumberShow more

Soligenix, Inc. (SNGX) Company Profile & Facts Yahoo Finance

8 hours ago Ca.finance.yahoo.com Show details

See the company profile for Soligenix, Inc. (SNGX) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their compensation.

Category: Contact NumberShow more

IND 20212 (032599) PHASE 2: ORBEC (ORAL BDP)PATIENTS

5 hours ago Sbir.gov Show details

(03-25-99The proposed open-label, multi-center, two-part Phase 2 clinical study is designed to evaluate the potential of orBec (R), a novel formulation of oral beclomethasone 17,21- dipropionate (BDP), as a treatment for chronic gastrointestinal cGVHD. OrBec (R), as developed by Soligenix, is formulated as two separate drug products for oral

Category: Contact NumberShow more

Soligenix Announces Publication Demonstrating Enduring

Just Now Wfmz.com Show details

PRINCETON, N.J., Nov. 4, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products

Category: Contact NumberShow more

HyBryte™ FLASH Study Selected as a 'Top Poster' Winner for

8 hours ago Wfmz.com Show details

PRINCETON, N.J., Oct. 12, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products

Category: Contact NumberShow more

Zacks Small Cap Research SNGX: Durable Immunity for

5 hours ago Scr.zacks.com Show details

By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update RiVax® Demonstrates Durable Immunity in Mouse Model On November 4, 2021, Soligenix, Inc. (NASDAQ:SNGX) announced the publication of preclinical studies for RiVax®, the company’s heat stable ricin toxin vaccine) that showed durable …

Category: Contact NumberShow more

Soligenix, Inc. (SNGX) Stock Price, News, Quote, Chart

Just Now Stockstelegraph.com Show details

Soligenix, Inc. (SNGX) stock rallied over 0.12% intraday to trade at $0.86 a share on NASDAQ. The stock opened with a gain of 0.00% at $0.86 and touched an intraday high of $0.9120, rising 6.05% against the last close of $0.86. The stock went to a low of $0.8550 during the session.

Category: Contact NumberShow more

Soligenix Stock Analysis 2021 SNGX Macroaxis

5 hours ago Macroaxis.com Show details

Soligenix generated a negative expected return over the last 90 days: Soligenix has some characteristics of a very speculative penny stock: Soligenix has high historical volatility and very poor performance: Soligenix has a very high chance of going through financial distress in the upcoming years: The company reported the previous year's revenue of 1.29 M.Net Loss for …

Category: Contact NumberShow more

SNGX Competitors and Alternatives 2021 (Soligenix

5 hours ago Marketbeat.com Show details

Comparatively, 10.3% of Soligenix shares are owned by institutional investors. 13.2% of Clever Leaves shares are owned by insiders. Comparatively, 2.9% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Category: Contact NumberShow more

FORM D SEC

3 hours ago Sec.gov Show details

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996

Category: Contact NumberShow more

What Are Analyst Opinions Regarding Soligenix Inc. (SNGX

1 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 40.08 million. SNGX does have institutional investors; and they hold 10.20% of the stock. Soligenix Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 3,000 shares.

Category: Contact NumberShow more

Thermostable Vaccine Technology Platform to be Presented

2 hours ago Marketwatch.com Show details

021-11-01PRINCETON, N.J., Nov. 1, 2021 /PRNewswire via COMTEX/ -- PRINCETON, N.J., Nov. 1, 2021 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the

Category: Tech SupportShow more

Soligenix Announces Successful Protection using a Bivalent

6 hours ago Biospace.com Show details

PRINCETON, N.J., Dec. 2, 2021 /PRNewswire/ -- Soligenix (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today 100% protection of non-human primates (NHPs) against lethal Sudan …

Category: Contact NumberShow more

Soligenix Announces Successful Protection using a Bivalent

3 hours ago Finance.yahoo.com Show details

Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Popular Brands

Sharp
Shell
Sap
Sgs
Sabb
Sea